EVI’s success rests largely on the strength of our pipeline of vaccines under development. EVI manages its vaccine candidate portfolio by:
- Maintaining diversity, so that the portfolio is not focused on a narrow range of candidates with similar characteristics
- Rigorous selection of candidates by an independent Scientific Advisory Committee at each stage of progression, so that only the best leads are fed in, and candidates not meeting demanding specifications are weeded out early on
- Balancing the number of projects supported with available resources.
EVI´s portfolio currently includes vaccines directed against diseases/pathogens such as malaria, dengue, zika, influenza and leishmaniasis.